Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Caitlin Clark averaged a career-best 22.3 points per game in the regular season for the…
VIDEO SHOWS: STILL PHOTOS OF U..S PRESIDENT DONALD TRUMP DEPARTING WHITE HOUSE AND EN ROUTE…
AIR CRASH IN SOUTHWEST OF DEMOCRATIC REPUBLIC OF CONGO HAS KILLED 17 PEOPLE, INCLUDING TWO…
VIDEO SHOWS: VARIOUS STILL PHOTOS OF TRUMP AT THE UNIVERSITY OF TENNESSEE VS. UNIVERSITY OF…
SHANGHAI, Sept 26 (Reuters) - The United States and China have agreed to reduce tariffs…
Mets 7, Nationals 1 Mets ab r h rbi bb so avg Lindor DH 4…